<DOC>
	<DOCNO>NCT00730795</DOCNO>
	<brief_summary>This Phase I study evaluate safety immunogenicity two dos GSK Biologicals ' candidate TB vaccine ( 692342 ) accord 0 , 1 , 2 month schedule PPD-negative adult .</brief_summary>
	<brief_title>Safety Immunogenicity Candidate Tuberculosis ( TB ) Vaccine Given PPD-Negative Adults</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy male female 18 40 year age time screen Negative PPD skin test screening . Subjects must chest Xray show evidence pulmonary pathology . Female subject childbearing potential must negative serum pregnancy test screening , must breastfeed require use adequate contraception enrolment till 1 month dose 3 . Screening laboratory value must within laboratory normal range . Negative human immunodeficiency virus1 2 ( HIV 1/2 ) antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . Subjects must give write informed consent . Subjects must willing make evaluation visit , readily reachable telephone personal contact study site personnel permanent address . Subjects ' resting seat vital sign must within protocoldefined range . History prior Bacillus CalmetteGu√©rin ( BCG ) vaccination . History document exposure Mycobacterium tuberculosis . History previous administration experimental Mycobacterium tuberculosis vaccine previous exposure experimental product contain component experimental vaccine . History employment healthcare facility capacity direct indirect contact TB patient . Administration immunoglobulins immunotherapy within 3 month precede first dose study vaccination , and/or blood product within 4 month precede HIV screening , plan administration study period . Use St. John 's Wort within six month Day 0 visit plan administration study period . Participation another experimental protocol and/or receipt investigational product within 30 day prior Day 0 . History autoimmune disease cause immunosuppressive state . History acute chronic illness medication , opinion Investigator , may interfere evaluation safety immunogenicity vaccine . History significant psychiatric illness . Current drug alcohol abuse History previous anaphylaxis severe allergic reaction vaccine allergen . Subjects , opinion investigator , significantly increase risk noncooperation requirement study protocol . Any chronic drug therapy continue study period , exception vitamin and/or dietary supplement ( include mineral preparation calcium carbonate ) , herbal medication except St. John 's Wort , birth control pill , antihistamine seasonal allergy , SSRIs ( e.g . Prozac , Zoloft , Paxil ) , NSAIDs ( e.g . aspirin , ibuprofen ) , acetominophen . Chronic administration ( defined 14 day total ) immunosuppressant immune modify drug within six month prior first vaccine dose . History chronic intermittently recur illness migraine headache , diabetes , heart disease , asthma . Current administration antiTB prophylaxis therapy . History administration live attenuate virus vaccine within 30 day enrollment . History administration subunit kill vaccine within 14 day enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
</DOC>